CVS Health Corporation: Finanzdaten Prognosen Schätzungen und Erwartungen | 859034 | US1266501006 | MarketScreener (2024)

Markt geschlossen - Nyse

Andere Börsenplätze

22:00:02 05.07.2024
% 5 Tage % 1. Jan.
56,62 USD -0,14% CVS Health Corporation: Finanzdaten Prognosen Schätzungen und Erwartungen | 859034 | US1266501006 | MarketScreener (1) -4,13% -28,29%
27.06. Walgreens senkt Gewinnprognose für 2024 und kündigt Filialschließungen an RE
27.06. Walgreens senkt Gewinnprognose für 2024 wegen schlechter als erwarteter Verbraucherausgaben RE

Bewertung

Steuerjahr: Dezember 2019 2020 2021 2022 2023 2024 2025 2026
Marktwert 1 96.649 89.399 136.274 122.449 101.613 71.079 - -
Unternehmenswert 1 159.446 146.192 179.925 160.658 151.768 120.271 116.891 109.911
KGV 14,6x 12,5x 17,3x 29,7x 12,2x 10,3x 8,54x 7,35x
Rendite 2,69% 2,93% 1,94% 2,36% 3,06% 4,7% 4,87% 5,29%
Marktkapitalisierung / Umsatz 0,38x 0,33x 0,47x 0,38x 0,28x 0,19x 0,18x 0,17x
Unternehmenswert / Umsatz 0,62x 0,54x 0,62x 0,5x 0,42x 0,33x 0,3x 0,27x
Unternehmenswert / EBITDA 9,23x 8,07x 9,2x 8,04x 7,59x 6,91x 6,09x 5,45x
Unternehmenswert / FCF 15,3x 10,9x 11,4x 11,9x 14,6x 13x 11,6x 9,65x
FCF Yield 6,52% 9,19% 8,75% 8,37% 6,85% 7,68% 8,66% 10,4%
Price to Book 1,51x 1,29x 1,81x 1,71x 1,33x 0,91x 0,85x 0,78x
Anz. der Aktien (in Tausend) 1.300.964 1.308.913 1.321.000 1.313.967 1.286.897 1.255.373 - -
Referenzkurs 2 74,29 68,30 103,2 93,19 78,96 56,62 56,62 56,62
Datum der Veröffentlichung 12.02.20 16.02.21 09.02.22 08.02.23 07.02.24 - - -

1USD in Millionen2USD

Schätzungen

Ergebnisentwicklung (Jahreszahlen)

Steuerjahr: Dezember 2019 2020 2021 2022 2023 2024 2025 2026
Umsatz 1 256.776 268.706 292.111 322.467 357.776 369.521 387.193 410.284
EBITDA 1 17.274 18.108 19.565 19.971 19.995 17.396 19.201 20.184
Betriebsergebnis (EBIT) 1 15.339 16.008 17.312 17.532 17.534 14.698 16.024 17.017
Umsatzrendite 5,97% 5,96% 5,93% 5,44% 4,9% 3,98% 4,14% 4,15%
Gewinn vor Steuern (EBT) 1 8.997 9.770 10.420 5.628 11.173 10.004 11.753 13.573
Nettoergebnis 1 6.634 7.179 7.910 4.149 8.344 7.382 8.690 10.038
Nettomarge 2,58% 2,67% 2,71% 1,29% 2,33% 2% 2,24% 2,45%
Gewinn pro Aktie 2 5,080 5,460 5,950 3,140 6,470 5,521 6,630 7,708
Free Cash Flow 1 10.391 13.428 15.745 13.450 10.395 9.237 10.118 11.393
FCF-Marge N 4,05% 5% 5,39% 4,17% 2,91% 2,5% 2,61% 2,78%
FCF Conversion (EBITDA) 60,15% 74,16% 80,48% 67,35% 51,99% 53,1% 52,7% 56,45%
FCF Conversion (Nettoergebnis) 156,63% 187,05% 199,05% 324,17% 124,58% 125,12% 116,43% 113,5%
Dividende pro Aktie 2 2,000 2,000 2,000 2,200 2,420 2,660 2,756 2,996
Datum der Veröffentlichung 12.02.20 16.02.21 09.02.22 08.02.23 07.02.24 - - -

1USD in Millionen2USD

Schätzungen

Ergebnisentwicklung (Quartalszahlen)

Steuerjahr: Dezember 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Umsatz 1 76.604 76.826 80.636 81.159 83.846 85.278 88.921 89.764 93.813 88.437 91.646 92.497 96.697 93.552 95.986
EBITDA 1 4.733 5.070 5.431 4.825 4.645 4.969 5.100 5.074 4.852 3.587 4.309 4.763 4.610 4.238 4.969
Betriebsergebnis (EBIT) 1 4.147 4.483 4.810 4.233 4.006 4.370 4.481 4.456 4.227 2.957 3.672 4.122 3.964 3.524 4.255
Umsatzrendite 5,41% 5,84% 5,97% 5,22% 4,78% 5,12% 5,04% 4,96% 4,51% 3,34% 4,01% 4,46% 4,1% 3,77% 4,43%
Gewinn vor Steuern (EBT) 1 1.570 2.946 4.029 -4.456 3.109 2.879 2.570 3.019 2.705 1.580 2.334 2.860 2.723 2.606 3.330
Nettoergebnis 1 1.306 2.312 2.951 -3.416 2.302 2.136 1.901 2.261 2.046 1.113 1.855 2.192 2.108 1.818 2.293
Nettomarge 1,7% 3,01% 3,66% -4,21% 2,75% 2,5% 2,14% 2,52% 2,18% 1,26% 2,02% 2,37% 2,18% 1,94% 2,39%
Gewinn pro Aktie 2 0,9800 1,740 2,230 -2,600 1,750 1,650 1,480 1,750 1,580 0,8800 1,380 1,645 1,622 1,437 1,818
Dividende pro Aktie 2 0,5000 0,5500 0,5500 0,5500 0,5500 0,6050 0,6050 0,6050 0,6050 0,6650 0,6664 0,6664 0,6664 0,7290 0,7290
Datum der Veröffentlichung 09.02.22 04.05.22 03.08.22 02.11.22 08.02.23 03.05.23 02.08.23 01.11.23 07.02.24 01.05.24 - - - - -

1USD in Millionen2USD

Schätzungen

Bilanzanalyse

Steuerjahr: Dezember 2019 2020 2021 2022 2023 2024 2025 2026
Nettoschuld 1 62.797 56.793 43.651 38.209 50.155 49.192 45.812 38.831
Nettoliquidität 1 - - - - - - - -
Verschuldungsgrad (Verbindlichkeiten/EBITDA) 3,635x 3,136x 2,231x 1,913x 2,508x 2,828x 2,386x 1,924x
Free Cash Flow 1 10.391 13.428 15.745 13.450 10.395 9.237 10.118 11.393
ROE (Nettogewinn/Eigenkapital) 15,1% 14,8% 15,5% 15,7% 15,2% 11,4% 11,9% 11,6%
ROA (Nettogewinn/Gesamtvermögen) 4,41% 4,35% 4,82% 4,99% 4,72% 3,61% 3,96% 4%
Aktiva 1 150.315 164.974 164.261 83.216 176.918 204.586 219.421 250.941
Buchwert je Aktie 2 49,10 53,00 56,90 54,60 59,40 62,50 66,30 72,80
Cash Flow pro Aktie 2 9,850 12,10 13,70 12,20 10,40 7,930 8,810 10,70
Capex 1 2.457 2.437 2.520 2.727 3.031 3.012 3.143 3.286
Capex / Umsatz 0,96% 0,91% 0,86% 0,85% 0,85% 0,82% 0,81% 0,8%
Datum der Veröffentlichung 12.02.20 16.02.21 09.02.22 08.02.23 07.02.24 - - -

1USD in Millionen2USD

Schätzungen

Gewinn pro Aktie & Dividende

Historische Entwicklung KGV

Entwicklung der Dividendenrendite

Entwicklung Unternehmenswert / EBITDA

Ratings für CVS Health Corporation

Trading Rating

Investment Rating

ESG Refinitiv

B-

Mehr Ratings

Analystenschätzungen

Verkaufen

CVS Health Corporation: Finanzdaten Prognosen Schätzungen und Erwartungen | 859034 | US1266501006 | MarketScreener (2)

Kaufen

Durchschnittl. Empfehlung

AUFSTOCKEN

Anzahl Analysten

29

Letzter Schlusskurs

56,62USD

Mittleres Kursziel

69,1USD

Abstand / Mittleres Kursziel

+22,03%

Analystenschätzungen

Verlauf des Gewinns je Aktie

Entwicklung der Schätzungen

Quartalsgewinne - Abweichungsrate

Unternehmenstermine

Sektor Einrichtungen und Dienste des Gesundheitswesens - Andere

% 1. Jan. Kap.

CVS HEALTH CORPORATION

-28,29% 71,08Mrd.

HCA HEALTHCARE, INC.

+18,33% 83,89Mrd.

DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY

+0,99% 26,77Mrd.

+3,67% 17,74Mrd.

LABCORP HOLDINGS INC.

-9,99% 17,24Mrd.

QUEST DIAGNOSTICS INCORPORATED

+1,86% 15,6Mrd.

NATERA, INC.

+79,98% 13,84Mrd.

PURE HEALTH HOLDING

-25,09% 12,92Mrd.

TENET HEALTHCARE CORPORATION

+74,41% 12,87Mrd.

UNIVERSAL HEALTH SERVICES, INC.

+18,69% 12,11Mrd.

Einrichtungen und Dienste des Gesundheitswesens - Andere

  1. Börse
  2. Aktien
  3. 859034 Aktie
  4. Finanzen CVS Health Corporation
Profitieren Sie von unseren kostenlosen Inhalten, um Ihre Investitionen abzusichern und deren Performance zu steigern Meine Investitionen sichern

CVS Health Corporation: Finanzdaten Prognosen Schätzungen und Erwartungen | 859034 | US1266501006 | MarketScreener (13)

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'de_DE');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '12230');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });
CVS Health Corporation: Finanzdaten Prognosen Schätzungen und Erwartungen | 859034 | US1266501006 | MarketScreener (2024)

FAQs

Is CVS stock expected to rise? ›

Stock Price Forecast

The 20 analysts with 12-month price forecasts for CVS Health stock have an average target of 76.1, with a low estimate of 58 and a high estimate of 100. The average target predicts an increase of 34.40% from the current stock price of 56.62.

How is CVS doing financially? ›

Total revenues increased 12.3% and 10.2% for the three months and year ended December 31, 2023, respectively, compared to the prior year primarily driven by pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health.

What is the earnings forecast for CVS? ›

CVS Earnings Forecast

Next quarter's earnings estimate for CVS is $1.76 with a range of $1.60 to $2.02. The previous quarter's EPS was $1.31.

Is CVS in debt? ›

Total debt on the balance sheet as of March 2024 : $81.79 B

According to CVS Health's latest financial reports the company's total debt is $81.79 B. A company's total debt is the sum of all current and non-current debts.

Is CVS merging with target? ›

1 On December 16, 2015, CVS Health Corporation closed its acquisition of 1672 Target in-store pharmacies in 47 states. Those 1672 pharmacies were accordingly operated through a store-within-a-store format, branded as CVS/pharmacy (Target, 2015).

What will CVS stock be in 5 years? ›

CVS Health stock price stood at $56.64

According to the latest long-term forecast, CVS Health price will hit $60 by the end of 2024 and then $75 by the end of 2025. CVS Health will rise to $80 within the year of 2026, $85 in 2027, $95 in 2028, $100 in 2029, $110 in 2030, $125 in 2031 and $150 in 2035.

What is the CVS controversy? ›

CVS Health Corporation Agreed to Pay $2 Million for Allegedly Violating the Civil Monetary Penalties Law by Improperly Rejecting, Denying, or Reducing Claims for Dual Eligible Federal Health Care Program Beneficiaries.

What is CVS strategy for 2024? ›

CVS has announced its plan to reduce its workforce by 5,000 individuals and close approximately 900 stores between 2022 and 2024 (out of which approximately 600 locations closed last year). Employees affected by the closures will be offered equivalent positions elsewhere.

Is CVS a good company to invest in? ›

CVS Health (CVS -0.14%) is a top pharmacy retailer in the U.S., and over the years, it has been expanding its operations to go deeper into healthcare. The stock also provides investors with a dividend that yields 4.3%, which is more than double the S&P 500 average of 1.3%.

Is CVS a growing company? ›

For all of last year, CVS revenues increased 10.9% to $357.8 billion and profits nearly doubled in 2023 to $8.3 billion compared to $4.3 billion in 2022.

Is CVS Health overvalued? ›

Compared to the current market price of 56.62 USD, CVS Health Corp is Undervalued by 64%.

Is CVS financially stable? ›

CVS Health has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is.

Is CVS stock recession proof? ›

CVS exhibits a recession-proof business model, which should keep enabling the company to produce robust results even during challenging market environments. Its latest quarter portrayed this, with earnings-per-share destined to reach a new all-time high this year.

What country owns CVS? ›

CVS Health Corporation (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands.

Is CVS Group a buy or sell? ›

CVS Group PLC has 44.06% upside potential, based on the analysts' average price target. Is CVS Group PLC a Buy, Sell or Hold? CVS Group PLC has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.

Who is CVS buying out? ›

March 30, 2023 - CVS has finalized its acquisition of the home healthcare company Signify Health, which aims to accelerate value-based care and improve health outcomes.

What is the fair value of CVS stock? ›

As of 2024-07-06, the Fair Value of CVS Health Corp (CVS) is 145.79 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 56.62 USD, the upside of CVS Health Corp is 157.5%.

Top Articles
Latest Posts
Article information

Author: Trent Wehner

Last Updated:

Views: 6253

Rating: 4.6 / 5 (56 voted)

Reviews: 95% of readers found this page helpful

Author information

Name: Trent Wehner

Birthday: 1993-03-14

Address: 872 Kevin Squares, New Codyville, AK 01785-0416

Phone: +18698800304764

Job: Senior Farming Developer

Hobby: Paintball, Calligraphy, Hunting, Flying disc, Lapidary, Rafting, Inline skating

Introduction: My name is Trent Wehner, I am a talented, brainy, zealous, light, funny, gleaming, attractive person who loves writing and wants to share my knowledge and understanding with you.